Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (2993)	12/26/2007 5:21:52 PM
From: Icebrg	Respond to of 3044

Millennium Pharmaceuticals "outperform" Wednesday, December 26, 2007 6:31:38 AM ET Robert W. Baird NEW YORK, December 26 (newratings.com) - Analyst Christopher Raymond of Robert W Baird reiterates his "outperform" rating on Millennium Pharmaceuticals Inc (MLNM.NAS). The target price is set to $18. In a research note published this morning, the analyst mentions that the November institutional prescription data released by Wolters Kluwer Health indicates WAC dollar sales of $22 million for Millennium Pharmaceuticals’ Velcade. Thus the drug’s WAC dollar sales are sequentially up 27% in the first two months of 4Q07, the analyst says. If this trend continues, Millennium Pharmaceuticals may generate $80 million in Velcade revenues in 4Q07, ahead of the consensus expectations, Robert W Baird adds.

To: Icebrg who wrote (2993)	1/4/2008 3:00:49 AM
From: Icebrg	Respond to of 3044

Millennium Pharmaceuticals "outperform" Thursday, January 03, 2008 7:13:55 AM ET Robert W. Baird NEW YORK, January 3 (newratings.com) - Analysts at Robert W Baird reiterate their "outperform" rating on Millennium Pharmaceuticals Inc (MLNM.NAS). The target price is set to $18. In a research note published this morning, the analysts mention that the Velcade revenue estimates for 4Q07 and 2008 have been raised marginally to $75 million and $325 million, respectively. While the robust Wolters-Kluwer Health prescription data for October and November suggests Velcade revenues of about $80 million in 4Q07, this data has not been completely reliable, the analysts say. Millennium Pharmaceuticals may provide conservative and wide-ranging guidance for FY08 Velcade revenues, Robert W Baird adds.

To: Icebrg who wrote (2993)	2/25/2008 2:11:13 PM
From: Icebrg	Respond to of 3044

>>MORGAN STANLEY DOWNS MLNM..AS OVERVALUED! 21-Dec-07 09:17 am >> [Someone will end up having to explain why there are eggs on the face] Analyst Sees Velcade Sales Doubling Monday February 25, 11:12 am ET FBR Analyst Says Millenium Pharma Could Double Sales of Cancer Drug Velcade, Shares Rise NEW YORK (AP) -- Shares of Millennium Pharmaceuticals Inc. rose 5 percent Monday, as a Friedman, Billings, Ramsey analyst said the biopharmaceutical company is on the verge of doubling sales of its main driver, the blood cancer drug Velcade. In December, Millenium shares surged after a late-stage study of multiple myeloma drug Velcade quadrupled complete remission rates when used as an initial treatment. Velcade is already approved in the U.S. to treat patients who have taken at least one treatment, but the FDA agreed to speed its review as an initial treatment. Approval is now expected around the middle of this year. FBR's Jim Reddoch maintained his "Outperform" rating and $20 price target on the stock, saying first-line approval opens Millenium up to an entirely new market and one in which patients would receive nearly double the number of Velcade injections they currently receive as a second-line treatment. Reddoch expects Velcade sales to beat the $345 million top end of guidance this year. Millennium has forecast sales of $320 million to $345 million, representing growth of 20 percent to 30 percent. Reddoch also said the company has heard investor concerns about its sizable research and development budget and is looking for ways to streamline it, possibly through drug development partnerships.